SK18932001A3 - Farmaceutický komplex - Google Patents

Farmaceutický komplex Download PDF

Info

Publication number
SK18932001A3
SK18932001A3 SK1893-2001A SK18932001A SK18932001A3 SK 18932001 A3 SK18932001 A3 SK 18932001A3 SK 18932001 A SK18932001 A SK 18932001A SK 18932001 A3 SK18932001 A3 SK 18932001A3
Authority
SK
Slovakia
Prior art keywords
composition
eletriptan
composition according
cyclodextrin
pharmaceutically acceptable
Prior art date
Application number
SK1893-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Anne Billotte
Original Assignee
Pfizer, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Inc. filed Critical Pfizer, Inc.
Publication of SK18932001A3 publication Critical patent/SK18932001A3/sk

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1893-2001A 1999-06-29 2000-06-02 Farmaceutický komplex SK18932001A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9915231.6A GB9915231D0 (en) 1999-06-29 1999-06-29 Pharmaceutical complex
PCT/IB2000/000746 WO2001000243A1 (en) 1999-06-29 2000-06-02 Pharmaceutical complex

Publications (1)

Publication Number Publication Date
SK18932001A3 true SK18932001A3 (sk) 2002-09-10

Family

ID=10856302

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1893-2001A SK18932001A3 (sk) 1999-06-29 2000-06-02 Farmaceutický komplex

Country Status (44)

Country Link
US (2) US6713461B1 (cs)
EP (1) EP1189640B1 (cs)
JP (2) JP4454900B2 (cs)
KR (1) KR20020015067A (cs)
CN (1) CN1198654C (cs)
AP (1) AP2001002369A0 (cs)
AR (1) AR033337A1 (cs)
AT (1) ATE290884T1 (cs)
AU (1) AU770169B2 (cs)
BG (1) BG106151A (cs)
BR (1) BR0011845A (cs)
CA (1) CA2376847C (cs)
CO (1) CO5170494A1 (cs)
CZ (1) CZ20014572A3 (cs)
DE (1) DE60018744T2 (cs)
DZ (1) DZ3320A1 (cs)
EA (1) EA003908B1 (cs)
EC (1) ECSP003551A (cs)
EE (1) EE200100697A (cs)
ES (1) ES2235879T3 (cs)
GB (1) GB9915231D0 (cs)
GE (1) GEP20043377B (cs)
GT (1) GT200000102A (cs)
HR (1) HRP20010951A2 (cs)
HU (1) HUP0201629A3 (cs)
IL (1) IL146341A0 (cs)
IS (1) IS6163A (cs)
MA (1) MA26801A1 (cs)
MX (1) MXPA01013274A (cs)
NO (1) NO20016430L (cs)
NZ (1) NZ515235A (cs)
OA (1) OA11964A (cs)
PA (1) PA8496801A1 (cs)
PE (1) PE20010346A1 (cs)
PL (1) PL352902A1 (cs)
SK (1) SK18932001A3 (cs)
SV (1) SV2002000112A (cs)
TN (1) TNSN00142A1 (cs)
TR (1) TR200103827T2 (cs)
UA (1) UA66932C2 (cs)
UY (1) UY26224A1 (cs)
WO (1) WO2001000243A1 (cs)
YU (1) YU87501A (cs)
ZA (1) ZA200110454B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CA2495864C (en) * 2002-08-20 2011-09-27 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CN1296391C (zh) * 2004-03-04 2007-01-24 中国人民解放军第二军医大学 氟代羧烷基环糊精醚类化合物及其制备方法和应用
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2017122161A1 (en) * 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
US20190224171A1 (en) * 2018-01-22 2019-07-25 Insys Development Company, Inc. Liquid rizatriptan compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024221A1 (en) 1986-08-18 1995-09-14 The Dow Chemical Company Bioactive and/or targeted dendrimer conjugates
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
HU211648A9 (en) 1990-03-28 1995-12-28 Chinoin Gyogyszer Es Vegyeszet Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
HU210921B (en) 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
WO1992006973A1 (en) 1990-10-15 1992-04-30 Pfizer Inc. Indole derivatives
CZ224995A3 (en) 1993-03-05 1995-12-13 Hexal Pharma Gmbh Crystalline cyclodextrin complexes of ranitidin hydrochloride, process of their preparation and pharmaceutical composition containing thereof
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
KR20000022239A (ko) 1996-07-11 2000-04-25 토마스 헤인 인돌 선택성 세로토닌 작용약을 함유한 내포 복합체
US5998462A (en) 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
ID24528A (id) 1997-07-03 2000-07-20 Pfizer Komposisi-komposisi obat farmasi yang mengandung eletriptan hemisulfat dan kafein
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex

Also Published As

Publication number Publication date
KR20020015067A (ko) 2002-02-27
US20040186076A1 (en) 2004-09-23
PA8496801A1 (es) 2002-02-21
CN1359303A (zh) 2002-07-17
EA200101106A1 (ru) 2002-06-27
GEP20043377B (en) 2004-04-13
MXPA01013274A (es) 2002-06-04
UY26224A1 (es) 2001-01-31
EE200100697A (et) 2003-02-17
JP4454900B2 (ja) 2010-04-21
TR200103827T2 (tr) 2002-05-21
CA2376847C (en) 2007-09-25
HRP20010951A2 (en) 2005-04-30
NO20016430D0 (no) 2001-12-28
NZ515235A (en) 2003-08-29
HUP0201629A2 (hu) 2003-03-28
CA2376847A1 (en) 2001-01-04
DE60018744T2 (de) 2006-05-18
EP1189640A1 (en) 2002-03-27
IS6163A (is) 2001-11-16
EP1189640B1 (en) 2005-03-16
BR0011845A (pt) 2002-03-05
DE60018744D1 (de) 2005-04-21
YU87501A (sh) 2004-05-12
DZ3320A1 (fr) 2001-01-04
PL352902A1 (en) 2003-09-22
ZA200110454B (en) 2002-12-20
JP2006257091A (ja) 2006-09-28
UA66932C2 (en) 2004-06-15
ECSP003551A (es) 2002-01-25
BG106151A (en) 2002-05-31
SV2002000112A (es) 2002-02-05
CN1198654C (zh) 2005-04-27
WO2001000243A1 (en) 2001-01-04
HUP0201629A3 (en) 2003-11-28
MA26801A1 (fr) 2004-12-20
GB9915231D0 (en) 1999-09-01
ATE290884T1 (de) 2005-04-15
CO5170494A1 (es) 2002-06-27
AP2001002369A0 (en) 2001-12-31
EA003908B1 (ru) 2003-10-30
TNSN00142A1 (fr) 2005-11-10
CZ20014572A3 (cs) 2002-08-14
NO20016430L (no) 2002-02-26
ES2235879T3 (es) 2005-07-16
AU4774100A (en) 2001-01-31
GT200000102A (es) 2001-12-14
US6713461B1 (en) 2004-03-30
OA11964A (en) 2006-04-17
JP2003503364A (ja) 2003-01-28
AU770169B2 (en) 2004-02-12
AR033337A1 (es) 2003-12-17
PE20010346A1 (es) 2001-03-26
IL146341A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
AU712546B2 (en) Inclusion complex containing indole selective serotonin agonist
RU2400227C2 (ru) Состав, содержащий твердую дисперсию базедоксифен ацетата
US20050222086A1 (en) Alprazolam inclusion complexes and pharmaceutical composition thereof
JP2006257091A (ja) 医薬錯体
KR20060134146A (ko) 선택적 에스트로겐 수용체 모듈레이터로서의 바제독시펜아스코르베이트
JP3518601B2 (ja) エバスタイムまたはその類似体に基づく医薬組成物
CA2321369C (en) Dosing regimens for lasofoxifene
CZ2001357A3 (cs) Prevence recidivy migrény
AU659311B2 (en) The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
MXPA02008376A (es) Material cristalino.
JP2000072677A (ja) 抗真菌性組成物
JPS58116423A (ja) メタノプロスタサイクリン製剤組成物
JPH11508916A (ja) トリアゾリルメチル−インドールエチルアミン重硫酸塩
CN1225018A (zh) 含有吲哚选择性的5－羟色胺激动剂的包合配合物